Back to News
Market Impact: 0.32
ADARx Pharmaceuticals targets $1.74 billion valuation in US IPO
Source: reuters.com
IPOs & SPACsHealthcare & BiotechInvestor Sentiment & Positioning
ADARx Pharmaceuticals is targeting a valuation of up to $1.74 billion in a U.S. IPO. The planned listing signals strengthening investor appetite for biotechnology offerings, though pricing, deal size and timing were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Taiwan benchmark Taiex rises to record intraday high as tech stocks advance
- India Proprietary Trading Slumps on Auction Liquidity Woes, Trading Curbs
- Asia stocks rise tracking U.S. tech rally; Trump-Xi meeting eyed
- Intel surges 12% as CPU stocks rally. Here's what's driving the move
- Iran vows 'painful' retaliation as Trump piles on pressure ahead of UN General Assembly meeting
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Independent Research Firms: A Publishing System
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More